# US 2026/0159828 A1 · Ribonucleic acid purification methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0159828 A1
- Document ID: US20260159828A1
- Status: Published application
- Kind: A1
- Application number: 19/407,642
- Filed: 2025-12-03
- Published: 2026-06-11
- Earliest claimed: 2024-12-09
- Assignees: Cytiva US LLC
- Applicants: Cytiva US LLC
- Inventors: Aydin Kavara
- Web page: https://patentgrep.com/patent/US20260159828A1

## CPC

- C12N 15/101: {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- B01D 15/363: {Anion-exchange}
- B01D 15/426: {Specific type of solvent}
- G01N 2030/8827: {involving nucleic acids}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The presently claimed and described technology provides a chromatography method for purifying ribonucleic acid (RNA) using an elution buffer with a pH of at least about 10 and comprising at least about 0.80 M of at least one salt and a neutralizing solution.

## Claims

### Claim 1

A method for purifying ribonucleic acid (RNA) comprising:
passing a sample comprising RNA through a chromatography device, wherein at least a portion of the RNA binds to the chromatography device;
eluting the RNA from the chromatography device with an elution buffer,
wherein the elution buffer has a pH of at least about 10 and comprises at least about 0.80 M of at least one salt;
wherein the RNA is eluted into a neutralizing solution, wherein the neutralizing solution has a pH lower than the elution buffer; and
wherein the RNA remains intact after elution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the elution buffer further comprises a base selected from the group consisting of sodium hydroxide (NaOH), potassium hydroxide (KOH), calcium hydroxide (Ca(OH)2), magnesium hydroxide (Mg(OH)2), barium hydroxide (Ba(OH)2), cesium hydroxide (CsOH), and combinations thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the base is present in a concentration of between about 0.000098 M and 0.000102 M, alternatively about 0.0000982 M, alternatively about 0.0000984 M, alternatively about 0.0000986 M, alternatively about 0.0000988 M, alternatively about 0.000099 M, alternatively about 0.0000992 M, alternatively about 0.0000994 M, alternatively about 0.0000996 M, alternatively about 0.0000998 M, alternatively about 0.0001 M, alternatively about 0.0001002 M, alternatively about 0.0001004 M, alternatively about 0.0001006 M, alternatively about 0.0001008 M, alternatively about 0.000101 M, alternatively about 0.0001012 M, alternatively about 0.0001014 M, alternatively about 0.0001016 M, or alternatively about 0.0001018 M.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one salt is selected from the group consisting of ammonium chloride, potassium chloride, sodium chloride, magnesium chloride, magnesium sulfate, magnesium nitrate, sodium citrate, ammonium sulfate, and combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the salt is present in a concentration of between about 0.80 M and 1.20 M, alternatively about 0.82 M, alternatively about 0.84 M, alternatively about 0.86 M, alternatively about 0.88 M, alternatively about 0.90 M, alternatively about 0.92 M, alternatively about 0.94 M, alternatively about 0.96 M, alternatively about 0.98 M, alternatively about 1.00 M, alternatively about 1.02 M, alternatively about 1.04 M, alternatively about 1.06 M, alternatively about 1.08 M, alternatively about 1.10 M, alternatively about 1.12 M, alternatively about 1.14 M, alternatively about 1.16 M, or alternatively about 1.18 M.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pH of the elution buffer is about 10.5, alternatively about 11, alternatively about 11.5, or alternatively about 12.

### Claim 7 (depends on 1)

The method of claim 1, wherein the elution buffer further comprises at least one basic amino acid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the at least one basic amino acid is selected from the group consisting of arginine, histidine, and lysine.

### Claim 9 (depends on 1)

The method of claim 1, wherein the neutralizing solution comprises at least one buffering agent and/or a chelating agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the buffering agent and/or chelating agent is selected from the group consisting of Tris(hydroxymethyl)aminomethane (TRIS), 2-(N-Morpholino) ethanesulfonic acid (MES), 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), 3-(N-Morpholino) propanesulfonic acid (MOPS), N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPSO), N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES), Ethylenediaminetetraacetic acid (EDTA), and combinations thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the buffering agent and/or chelating agent is present in a concentration of between about 0.80 M and 1.20 M, alternatively about 0.82 M, alternatively about 0.84 M, alternatively about 0.86 M, alternatively about 0.88 M, alternatively about 0.90 M, alternatively about 0.92 M, alternatively about 0.94 M, alternatively about 0.96 M, alternatively about 0.98 M, alternatively about 1.00 M, alternatively about 1.02 M, alternatively about 1.04 M, alternatively about 1.06 M, alternatively about 1.08 M, alternatively about 1.10 M, alternatively about 1.12 M, alternatively about 1.14 M, alternatively about 1.16 M, or alternatively about 1.18 M.

### Claim 12 (depends on 9)

The method of claim 9, wherein the neutralizing solution has a pH of between about 7.5 and about 9.5; alternatively about 8.0;
alternatively about 8.5; or alternatively about 9.0.

### Claim 13 (depends on 12)

The method of claim 12, wherein the neutralizing solution comprises about 1.00 M Tris and has a pH of about 8.0.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method further comprises washing the chromatography device with a wash solution prior to eluting the RNA.

### Claim 15 (depends on 14)

The method of claim 14, wherein the wash solution comprises at least one salt is selected from the group consisting of ammonium chloride, potassium chloride, sodium chloride, magnesium chloride, magnesium sulfate, magnesium nitrate, sodium citrate, ammonium sulfate, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the salt is present in a concentration of between about 0.80 M and 1.20 M, alternatively about 0.82 M, alternatively about 0.84 M, alternatively about 0.86 M, alternatively about 0.88 M, alternatively about 0.90 M, alternatively about 0.92 M, alternatively about 0.94 M, alternatively about 0.96 M, alternatively about 0.98 M, alternatively about 1.00 M, alternatively about 1.02 M, alternatively about 1.04 M, alternatively about 1.06 M, alternatively about 1.08 M, alternatively about 1.10 M, alternatively about 1.12 M, alternatively about 1.14 M, alternatively about 1.16 M, or alternatively about 1.18 M.

### Claim 17 (depends on 1)

The method of claim 1, wherein the chromatography device comprises an ion exchange chromatography layer, membrane, or resin, wherein the portion of the RNA binds to the ion exchange layer, membrane, or resin.

### Claim 18 (depends on 17)

The method of claim 17, wherein the ion exchange chromatography layer, membrane, or resin is an anion exchange chromatography layer, membrane, or resin.

### Claim 19 (depends on 1)

The method of claim 1, wherein the RNA is selected from the group consisting of messenger RNA (mRNA), self-amplifying RNA (srRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), microRNA (miRNA), small interfering RNA (siRNA), long non-coding RNA (lncRNA), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA), small rDNA-derived RNA (srRNA)), circular RNA (circRNA), guide RNA (gRNA), and long guide RNA (long gRNA).

### Claim 20 (depends on 1)

The method of claim 1, wherein the RNA is synthesized via in vitro transcription (IVT) or cellular transcription.

### Claim 21 (depends on 20)

The method of claim 20, wherein the RNA from is synthesized from plasmid DNA (pDNA) via IVT.

### Claim 22 (depends on 21)

The method of claim 21, wherein the RNA is derived from bacterial culture, cells, cell culture, cell lysate, recombinant plasmids, genetically modified plasmids, or synthetic plasmids.

### Claim 23 (depends on 1)

The method of claim 1, wherein the method is carried out at temperature between about 20° C. and about 30° C.

### Claim 24

A kit for purifying RNA comprising a chromatography device, a elution buffer with a pH of at least about 10 and comprises at least about 0.80 M of at least one salt, a neutralizing solution with a pH lower than the elution buffer, and instructions for use.
